Objective-Plasma high-density lipoproteins (HDL) are potent antiatherogenic and anti-inflammatory particles. However, HDL particles are highly heterogenic in composition, and different HDL-mediated functions can be ascribed to different subclasses of HDL. Only a small HDL population contains apolipoprotein M (ApoM), which is the main plasma carrier of the bioactive lipid mediator sphingosine-1-phosphate (S1P). Vascular inflammation is modulated by S1P, but both proand anti-inflammatory roles have been ascribed to S1P. The goal of this study is to elucidate the role of ApoM and S1P in endothelial anti-inflammatory events related to HDL. Approach and Results-Aortic or brain human primary endothelial cells were challenged with tumor necrosis factor-α (TNF-α) as inflammatory stimuli. The presence of recombinant ApoM-bound S1P or ApoM-containing HDL reduced the abundance of adhesion molecules in the cell surface, whereas ApoM and ApoM-lacking HDL did not. Specifically, ApoM-bound S1P decreased vascular adhesion molecule-1 (VCAM-1) and E-selectin surface abundance but not intercellular adhesion molecule-1. Albumin, which is an alternative S1P carrier, was less efficient in inhibiting VCAM-1 than ApoM-bound S1P. The activation of the S1P receptor 1 was sufficient and required to promote anti-inflammation. Moreover, ApoM-bound S1P induced the rearrangement of the expression of S1P-related genes to counteract TNF-α. Functionally, HDL/ApoM/S1P limited monocyte adhesion to the endothelium and maintained endothelial barrier integrity under inflammatory conditions. Conclusions-ApoM-bound S1P is a key component of HDL and is responsible for several HDL-associated protective functions in the endothelium, including regulation of adhesion molecule abundance, leukocyte-endothelial adhesion, and endothelial barrier. Five different membrane-bound G-protein-coupled S1P receptors (S1PRs) are known, and binding of S1P to the receptors activates multiple receptor-specific downstream signaling pathways. In this way, S1P is able to regulate several biological processes, such as immune cell trafficking, angiogenesis, endothelial cell migration, and endothelial barrier function. 9 The role of S1P in the regulation of vascular inflammation has been studied, and contradictory results have been obtained, for example, direct stimulation by S1P is reported to increase the abundance of adhesion molecules, whereas other studies [10] [11] [12] show that S1P inhibits tumor necrosis factor-α (TNF-α) induction of adhesion molecules, such as E-selectin, ICAM-1, or VCAM-1.
A therosclerosis was initially considered to be a lipid accumulation disorder, but it is now evident that a strong inflammatory component is part of its pathobiology. Inflammatory activation of vascular cells causes endothelial dysfunction and disrupts barrier permeability. Critically, with the appearance of proinflammatory stimuli, the endothelial cells become activated and increase the abundance of adhesion molecules on their surfaces such as E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular adhesion molecule-1 (VCAM-1), which lead to the recruitment of proinflammatory immune cells to the vascular wall. 1, 2 High-density lipoproteins (HDLs) constitute a powerful antiatherogenic factor in humans and an inverse relationship between HDL levels, and the risk of cardiovascular events has been demonstrated in numerous epidemiological studies. The atheroprotective role of HDL was initially attributed to the reverse cholesterol transport function performed by HDL. However, the HDL particles are highly heterogenic in composition of proteins and lipids, and additional atheroprotective mechanisms have been described. 3 For instance, paraxonase 1, platelet-activating factor acetylhydrolase, and glutathione peroxidase are HDL-associated antioxidative enzymes. In addition, vitamin E and carotenoids are lipophilic antioxidants that are transported by HDL. 4 Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator involved in a variety of physiological responses, including vascular and immune function. In plasma, the S1P concentration is ≈0.9 μmol/L out of which the major part is transported by HDL particles (≈65%) and the rest by albumin (≈35%). 5 The HDL-associated S1P is carried by the apolipoprotein M (ApoM)-containing subfraction of HDL particles, which only represents ≈5% of the total HDL. ApoM is a member of the Lipocalin family having its structure being defined by an 8-stranded antiparallel β-barrel enclosing a hydrophobic binding pocket, where S1P is located. 6 An unusual property of ApoM is that its signal peptide is not cleaved off during
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The aim of this study is to characterize the role of S1P in the regulation of human endothelium inflammation taking into account that S1P is mostly bound to ApoM in plasma. Using recombinant human ApoM with or without bound S1P and isolated HDL containing or HDL lacking human ApoM (HDL +ApoM and HDL −ApoM , respectively), we demonstrate that ApoM-bound S1P is an anti-inflammatory complex acting via endothelial S1P1 receptors. This is the first work where human HDL +ApoM and HDL −ApoM are used to study human endothelial inflammation. In addition, we show that ApoM-bound S1P is a more potent anti-inflammatory than albumin-bound S1P.
Materials and Methods
Material and Methods are available in the online-only Data Supplement.
Results and Discussion

ApoM-Bound S1P Reduces Adhesion Molecules in Human Inflamed Endothelium
To assess the role of ApoM and S1P in endothelial inflammation, we produced soluble recombinant human ApoM in E coli, which was loaded with S1P. Then, we challenged primary human aortic endothelial cells (HAEC) with TNF-α for 4 hours to induce the expression of adhesion molecules to test if addition of ApoM or ApoM-bound S1P to the culture medium altered the mRNA expression of the adhesion molecules. As expected, TNF-α strongly induced the expression of all adhesion molecules tested: E-selectin, ICAM-1, and VCAM-1. However, the presence of ApoM-bound S1P significantly mitigated TNF-α induction of adhesion molecules in HAEC, whereas ApoM by itself did not have any regulatory effect on the expression of TNF-α-induced adhesion molecules ( Figure 1A ). To confirm that the ApoM-bound S1P decreased the surface expression of adhesion molecules in TNF-α-challenged HAEC, we performed flow cytometry experiments. Interestingly, this revealed that ApoM-bound S1P reduced the abundance of E-selectin and VCAM-1 in HAEC plasma membrane but did not suppress ICAM-1 ( Figure 1B  and 1C) . These results were also verified by Western blot analysis ( Figure IA and IB in the online-only Data Supplement).
Next, we investigated if ApoM-bound S1P-specific modulation of adhesion molecules in HAEC also occurs in other types of endothelium. For that, we used HBMEC/ciβ (conditionally immortalized human brain microvascular endothelial cells, clone β) and treated them with TNF-α or TNF-α in the presence of ApoM-bound S1P. Then we measured E-selectin and ICAM-1 by flow cytometry. As in HAEC, ApoM-bound S1P regulated E-selectin plasma membrane abundance in HBMEC/ciβ, but did not modify ICAM-1 ( Figure 1D ). Unfortunately, we could not detect any membrane staining for VCAM-1 in HBMEC/ciβ by flow cytometry. However, Western blot analysis showed that ApoM-S1P reduces the total amount of VCAM-1 in TNF-α-challenged HBMEC/ciβ ( Figure IC in the online-only Data Supplement).
The lack of regulation of ICAM-1 surface expression by ApoM-bound S1P in the endothelium despite decreased ICAM-1 mRNA may indicate some peculiarities of the human endothelium. For instance, lentivirus overexpression of ApoM in HepG2 hepatocytes suppresses TNF-α-induced expression of ICAM-1.
14 Moreover, Galvani et al 13 found that HDL containing ApoM significantly suppressed ICAM-1, but only after 5 or 6 hours of TNF-α stimulation and not at the 4-hour time point. However, Galvani et al 13 used mice HDL and HUVEC (human umbilical vein endothelial cells) cells to study ApoM/ S1P anti-inflammatory ability. Therefore, in addition to experimental time differences, HDL source and type of endothelial cells could contribute to the explanation of the difference in results. Taking together, these results suggest that E-selectin and VCAM-1 are primary targets of ApoM-bound S1P to counteract inflammation, and their suppression may be critical to stop the inflammatory process at an early phase, whereas ICAM-1 suppression may be part of a long-term response, which can also include E-selectin and VCAM-1.
Intriguingly, we found that the anti-inflammatory effect of ApoM-bound S1P was blocked by the addition of 10-fold excess of unloaded ApoM ( Figure II in the online-only Data Supplement). A possible explanation for this result is that ApoM interacts with the S1PR to deliver S1P and that the interaction is blocked by an excess of unloaded ApoM. However, most plasma ApoM contains S1P, and, therefore, this blockage is not expected in vivo.
Our results showed that ApoM per se did not have antiinflammatory properties and that ApoM-S1P complexes are required to achieve anti-inflammation in the endothelium. In ) and measured the concentration of S1P in these preparations. As expected, we found that S1P is mainly detected in HDL containing ApoM (Figure 2A ). We used these HDL preparations to investigate whether ApoM and S1P attenuate the increase of adhesion molecules on TNF-α stimulation in endothelial cells. Total HDL significantly decreased the amount of E-selectin ( Figure 2B ) and VCAM-1 ( Figure 2C TNF-α condition was set as 100% and used for normalization purposes. Error bars correspond to SD. E-selectin n=7 to 8, ANOVA on ranks P<0.001 followed by Dunn multiple comparison post hoc test; ICAM-1 n=4, 1-way ANOVA P=0.018 followed by Holm-Sidak multiple comparison post hoc test; VCAM-1 n=10 to 11, ANOVA on ranks P<0.001 followed by Dunn multiple comparison post hoc test. D, HBMEC/ciβ (conditionally immortalized human brain microvascular endothelial cells, clone β) were incubated with TNF-α 10 ng/mL±ApoM-bound S1P 0.5 μmol/L or ApoM 0.5 μmol/L for 4 h. Cells were analyzed by flow cytometry: E-selectin (left) and ICAM-1 (right). Data were normalized vs TNF-α condition and represented as means±SEM (E-selectin, n=3-6; ICAM-1, n=3-4). ANOVA on ranks P=0.008 for E-selectin graph and P=0.044 for ICAM-1 followed by Dunn multiple comparison post hoc test. *P<0.05.
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−ApoM neither affected E-selectin nor VCAM-1. In agreement with previous results on Figure 2C , HDL +ApoM also significantly lowered VCAM-1 surface expression ( Figure 2D ).
The absence of inhibition of VCAM-1 by HDL −ApoM is in agreement with results obtained by Galvani et al. 13 However, in contrast to Galvani et al 13 who applied HDL isolated from mice on HUVEC, we used human HDL on HAEC. Reconstituted HDL (rHDL) made of ApoA1 and phosphatidylcholine has also been reported to inhibit inflammatory adhesion markers in endothelial cells. 15, 16 However, the inhibitory effect mediated by rHDL required that the rHDL was preincubated with the endothelial cells before the stimulation with TNF-α and that the effect was time dependent. 16 Thus, the results obtained with rHDL concur with the now observed lack of anti-inflammatory properties of HDL −ApoM described in Figure 2B through 2D. The mechanisms explaining why rHDL attains anti-inflammatory effects on incubation with cultured endothelium remains to be elucidated. A theoretical possibility is that the rHDL takes up ApoM/S1P that potentially is synthesized in the endothelium.
If S1P is responsible for the decrease in surface-expressed E-selectin and VCAM-1, it is expected to be consumed during the experiment. Therefore, we measured S1P concentration in the cell supernatant by mass spectrometry at time zero and 4 hours later. We found that S1P concentration is reduced 6.4-fold after 4 hours ( Figure 2E ). These results confirm our hypothesis and further support the anti-inflammatory function of the ApoM-S1P complex. Together, all these data show that ApoM-bound S1P promotes anti-inflammation in the endothelium, whether it is part of an HDL particle or not.
ApoM-Bound S1P Improves Endothelial Function
Next, we asked whether the ApoM-bound S1P-dependent changes in adhesion molecule abundance have any functional impact in the endothelium. For that purpose, we performed monocyte-endothelial cell adhesion experiments. Fluorescently labeled THP-1 (human monocyte THP-1 cell line cells) monocytes were incubated over pretreated HAEC. Consistent with the observed changes in adhesion molecule abundance, TNF-α increases the number of adherent monocytes. This increase is counteracted by the presence of ApoM loaded with S1P, but not by unloaded ApoM (Figure 3A and 3B). In a similar way, total HDL reduced the amount of adherent monocytes. In contrast, HDL −ApoM did not significantly decrease monocyte-endothelial cell adhesion ( Figure 3C ). These findings are in line with results obtained in murine models and cell experiments, where it has been shown that the exogenous addition of S1P decreases monocyte-endothelium adhesion. [17] [18] [19] Our experiments confirm these previous reports and highlight the crucial role of ApoM in S1P biology.
To act as a selective barrier is one of the major functions of the vascular endothelium, and vascular leakage is a hallmark of inflammation. Because ApoM-bound S1P is involved in the maintenance of the endothelial barrier in basal conditions 5, 20 and endothelial permeability is increased under inflammatory conditions, 21 we wondered if ApoM-bound S1P can regulate endothelial permeability under inflammatory conditions. To that end, first we measured the resistance of ions going through the endothelial barrier (also known as TEER [trans-endothelial electric resistance]) and found that ApoM-bound S1P significantly restored the TNF-α-induced decrease in endothelial barrier resistance ( Figure 3D ). Then, we investigated whether the endothelial barrier improvement caused by ApoM-bound S1P applied also to macromolecules. Therefore, 70 kDa FITC (fluorescein isothiocyanate)-dextran (similar size to human albumin) was used to monitor HAEC barrier capacity. Recombinant ApoM-bound S1P and total HDL significantly suppressed TNF-α-induced leakage of FITC-dextran through the endothelial barrier. In contrast, neither recombinant ApoM without S1P nor HDL −ApoM was able to maintain endothelial barrier functionality ( Figure 3E and 3D) . Importantly, TNF-α does not significantly affect HAEC viability at the concentration and exposure time used in our experiments ( Figure III in the online-only Data Supplement). 21 Therefore, the changes observed can be ascribed to changes in permeability and not to cell death. These findings complement previous works, 5, 22 where increased extravasation in the lungs of ApoM knockout mice was described.
Together, these results support the concept that ApoM and S1P are key components of HDL and are required to promote proper endothelial functionality.
ApoM-Bound S1P Anti-Inflammatory Effect Goes Via S1P1 S1P signals through 5 different G-couple protein receptors (S1P1-5). Thus, to understand the anti-inflammatory role of ApoM-bound S1P in the endothelium, we first studied the expression of S1PR in the aortic endothelium by quantitative polymerase chain reaction. We found that HAEC express S1P1, S1P2 and S1P3, but do not express S1P4 or S1P5 ( Figure 4A ). In agreement with the previous reports, S1P1 predominates in the aortic endothelium.
10,23 Thus, we examined which S1P receptor/s are responsible for the ApoMbound S1P anti-inflammatory function For that end, we followed a pharmacological approach and used receptor-specific antagonists to block S1P signaling. E-selectin and VCAM-1 reduction caused by ApoM-bound S1P in TNF-α challenged HAEC was abolished by W146, an S1P1 antagonist ( Figure  4B ). In contrast, blockage of S1P2 (with JTE-013) or S1P3 (with CAY10444) did not have any effect (Figure 4C and 4D) . To confirm S1P1 participation in ApoM-bound S1P mediated anti-inflammation, we used SEW2871, an S1P1-specific agonist. SEW2871 mimicked the ApoM-bound S1P effect and reduced the abundance of E-selectin in the plasma membrane of HAEC. In addition, the use of CYM5541, a S1P3-specific agonist, did not modify endothelial inflammatory response.
Together, these data support the concept that the antiinflammatory ApoM-S1P complex acts through S1P1 to reduce adhesion molecule abundance in TNF-α-treated HAEC. This finding concurs with the recent discovery of HDL containing S1P limiting vascular inflammation in mice through S1P1.
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TNF-α and ApoM-Bound S1P Modify the Expression of S1P-Related Genes
To further explore the anti-inflammatory ability of ApoMbound S1P, we investigated if ApoM-S1P can modify the expression of S1P-related genes. It is known that proinflammatory stimuli modify S1PR.
24 S1P1 expression was induced by TNF-α, but this induction was not further altered by ApoM-bound S1P ( Figure 5A ). About S1P2 expression, S1P2 was also upregulated on TNF-α treatment, but TNF-α-dependent upregulation was significantly less prominent when ApoM-bound S1P was present ( Figure 5B ). This is particularly relevant because S1P2 mediates the induction of vascular permeability and vascular inflammation. [24] [25] [26] Remarkably, S1P3 expression was not significantly influenced by TNF-α. However, ApoM-bound S1P downregulated S1P3 expression in TNF-α-treated HAEC ( Figure 5C ). S1P3 plays a crucial role in endothelial inflammation and atherosclerosis, promoting leukocyte adhesion to the endothelium. 27, 28 However, another report gives S1P3 a dual pro/anti-inflammatory role. 11 Our results fit with S1P3 as a proinflammatory receptor. Therefore, reduction in S1P3 expression by ApoM-bound S1P could contribute to the creation of an anti-inflammatory environment. S1P4 expression and S1P5 expression were not detected in HAEC, either in basal condition or on TNF-α treatment. Together, these results show that ApoM-bound S1P provokes readjustments in S1PR expression to counteract TNF-α-induced inflammation.
Sphingosine kinase-1 (SK1, SPHK1) is the main enzyme responsible for S1P production. SPHK1 transcription increases on TNF-α stimulation 25 ( Figure 5D ). Even though an increase of SK1 activity has been related with an increase of E-selectin and VCAM-1 in the membrane of endothelial cells, 29 ApoMbound S1P further increased SPHK1 transcription, whereas the S1P-free ApoM did not ( Figure 5D ). To support SPHK1 transcription results, we measured the amount of S1P in the cellular lysates of HAEC treated with TNF-α in the presence of the ApoM-bound S1P or ApoM ( Figure 5E ). Remarkably, the profile of the cellular content of S1P matches with SPHK1 A C B D Figure 4 . Sphingosine-1-phosphate receptor 1 (S1P1) mediates anti-inflammatory effect of S1P in human endothelium. A, Relative expression of S1PR in HAEC. Total RNA was analyzed by quantitative polymerase chain reaction using Taqman probes for S1PR and normalized against GAPDH expression. A, Representative experiment of n=4 independent experiments. Error bars correspond to SD. B-D, Flow cytometry measurement of E-selectin and vascular adhesion molecule-1 (VCAM-1) in HAEC. Cells were preincubated with specific S1PR inhibitors at 5 μmol/L (W146 for S1P1 in B, JTE-013 for S1P2 in C, and CAY10444 for S1P3 in D) for 30 min and then challenged with tumor necrosis factor-α (TNF-α) 10 ng/mL±ApoM-bound S1P 0.5 μmol/L for 4 h. Data are represented as means±SEM (n=6-7 in B, n=5-7 in C, and n=5-7 in D). Mann-Whitney U test, but Student t test for E-selectin in C and D. E, HAEC were treated with TNF-α±SEW2871 5 μmol/L or CYM5541 5 μmol/L and analyzed for E-selectin by flow cytometry. Average of n=6 to 7 experiments±SEM is represented. ANOVA on ranks P=0.04 followed by Dunn multiple comparison post hoc test. *P<0.05. ApoM indicates apolipoprotein M. Figure 3 Continued. bound S1P 0.5 μmol/L. The transendothelial electric resistance was measured before stimulation and 4 and 8 h after stimulation. Data were normalized against nonstimulated cells and represented as means±SEM, n=4. Two-way ANOVA P=0.002 shows a significant difference between HAEC treated with TNF-α plus ApoM-bound S1P and HAEC only treated with TNF-α. E and F, HAEC were grown in inserts as in D, then treated with TNF-α 10 ng/mL±ApoM-bound S1P 0.5 μmol/L or ApoM 0.5 μmol/L in E or with TNF-α 10 ng/ mL±total human HDL 0.5 mg/mL or HDL − ApoM 0.5 mg/mL in F for 6 h. FITC (fluorescein isothiocyanate)-Dextran was added to the upper chamber, then lower-chamber media was collected and fluorescence measured (EX λ 480-EM λ 520). TNF-α condition was set to 100% and used for normalization purposes. Error bars correspond to SEM, n=3 in E and n=6 in F. One-way ANOVA P=0.007 for E and P=0.002 for F followed by Holm-Sidak multiple comparison post hoc test. *P<0.05.
expression. This is an intriguing finding. It is possible that ApoM-bound S1P delivers S1P to S1P1 what induces an increased synthesis of S1P by SK1 thereby creating a positive feedback that promotes anti-inflammation in the endothelium. Thus, the increased intracellular S1P may either be newly synthesized S1P by the cells because of increased SPHK1 or the result of uptake from the ApoM-bound S1P.
Furthermore, we analyzed the expression of APOM and APOA1 in HAEC. As expected, APOA1 was not expressed in HAEC, but, surprisingly, ApoM mRNA was detected in HAEC. However, none of the treatments modified its expression. Then, we wondered if APOM is expressed by other types of endothelial cells. Affirmatively, we find ApoM mRNA expression in HBMEC/ciβ and HUVEC (data not shown). To investigate whether the ApoM protein could be detected in cell lysates or in the cell medium, we analyzed cell lysates with a sensitive Western blotting (5 µg of total protein loaded) and the cell medium with an enzyme-linked immunosorbent assay (ELISA). However, we could neither detect ApoM protein in the cell lysates nor in the HAEC supernatants. Thus, we conclude that HAEC medium did not contain ApoM levels >0.1 nmol/L (detection limit in the ELISA 30 ) and intracellularly >3 ng/5 µg protein (detection limit by the Western) under the experimental conditions of this work (serum-free media). However, it is possible that the presence of an extracellular ApoM acceptor such as HDL can stimulate endothelial cells to produce and secrete ApoM in vivo. In support of this hypothesis, Ahnström et al 31 showed in vitro that HDL was required for the secretion of full-length recombinant ApoM, the uncleaved signal peptide retaining ApoM in the cells in the absence of extracellular HDL. More investigations are required to characterize endothelial-derived ApoM because the results of the RT-PCR suggested that the endothelium could be a potential source of plasma ApoM. In consonance, vascular endothelium has the S1P transporter Spns2, and, therefore, it could be a contributor of plasma S1P in humans. 32, 33 Liver is the main source of ApoM, 34, 35 and, interestingly, ApoM and S1P levels are reduced in human plasma during sepsis. [36] [37] [38] The fact that APOM expression is not affected by TNF-α suggests that endothelial-derived ApoM may follow a distinct expression pattern, when compared with liver ApoM. 
ApoM-Bound S1P Does Not Modify Cytokine Release by Endothelial Cells
Next, we investigated whether ApoM-bound S1P has any effects on cytokine secretion as part of its anti-inflammatory activity. For that purpose, we collected cell medium from stimulated HAEC after 4 hours of treatment and as initial approximation performed a qualitative Western blot-based cytokine array ( Figure 6A ). In medium from nonstimulated cells, only MIF (macrophage migration inhibitory factor) was detected. Up to 8 cytokines (GRO-α [growth-regulated alpha protein], interleukin-6 [IL-6], IL-8, IL-13, monocyte chemoattractant protein-1 [MCP-1], MIF, Serpin E1, and TNF-α) were identified in medium from TNF-α or TNF-α plus ApoMbound S1P-treated HAEC. Then, we performed ELISAs with the same supernatants to obtain quantitative data. We found that GRO-α, IL-6, and MCP-1 were induced by TNF-α but not further modified by ApoM-bound S1P or ApoM ( Figure  2B through 2D, respectively) . Unfortunately, the presence of IL-13 and MIF was not confirmed by ELISA. In addition, we did not detect GM-CSF (granulocyte-macrophage colonystimulating factor) or IL-10 in any condition. Endothelial cells produce TNF-α after stimulation with proinflammatory cytokines or lipopolysaccharides. 39, 40 Therefore, we measured the expression of TNFA by quantitative polymerase chain reaction. HAEC did not express TNFA under basal condition; although TNFA expression was measurable after exogenous TNF-α stimulation, we did not detect any significant change caused by ApoM-bound S1P ( Figure  6E ). Thus, we conclude that ApoM-bound S1P does not affect cytokine release by endothelial cells on TNF-α stimulation.
S1P Carrier-Dependent Regulation of Inflammation
S1P is mainly carried by HDL (bound to ApoM) in plasma, but a fraction is bound to albumin. Therefore, we were interested to test if albumin-bound S1P could also decrease TNF-α-induced upregulation of VCAM-1 in the plasma membrane as ApoM-bound S1P does. To that end, we loaded human albumin with S1P and then compared the effect of equal amount of S1P bound to albumin, recombinant ApoM, or total HDL on TNF-α-induced VCAM-1 ( Figure 7A ). Remarkably, we found that at the highest concentration studied, 0.5 μmol/L, ApoM-bound S1P and albumin-bound S1P were equally efficient. However, when the S1P concentration was 0.1 μmol/L, only ApoM-bound S1P (both, soluble, or in HDL) significantly reduced VCAM-1, whereas albumin-bound S1P did not ( Figure 7B ). This result suggests that the transfer of S1P to S1P1 is more favorable when S1P is bound to ApoM at low concentrations. Alternatively, another explanation comes from the fact that HDL reduces the rate of S1P1 degradation when compared with albumin-S1P under basal conditions 20 or TNF-α stimulation. 13 Interestingly, ApoM-bound S1P was significantly more efficient than total HDL ( Figure 7A ) as a whole and specifically at S1P 0.05 µmol/L. It is possible that the HDL size limits the ApoM and S1P1 interaction. S1P 0.01 µmol/L was not statistically significant for any of the treatments.
Given that (1) exogenous stimulation of noncarrier-mediated S1P on endothelial cells is often described as a proinflammatory stimulus, [10] [11] [12] (2) most albumin molecules in plasma do not carry S1P, (3) S1P is largely bound to ApoM, and (4) ApoM-bound S1P is more potent anti-inflammatory than albumin-S1P, we conclude that ApoM takes up a prominent role in S1P biology and vascular homeostasis.
ApoM-Bound S1P Reduces Endothelial Inflammation
Multiple studies have shown the implication of S1P in the regulation of endothelial inflammation. However, because of the large heterogeneity in S1P concentration used, time of analysis, and model of study, the conclusions go from S1P as a proinflammatory molecule to a potent anti-inflammatory. A crucial aspect is that S1P was mostly administrated as a free molecule, for instance, [10] [11] [12] 17 whereas plasma S1P is always bound to ApoM or to a lesser extent to albumin. Only recently, a study showed that monocyte chemoattractant protein-1 purified from ApoM knock-out mice does not reduce TNF-α-induced inflammation in HUVEC, whereas wild-type mice HDL successfully do. 13 Here, we go 1 step further and report that the anti-inflammatory role of human HDL in human endothelial cells is because of ApoM-bound S1P.
ApoM-Bound S1P, S1P1, and Other S1PR in Vascular Homeostasis S1P1 is the most abundant S1PR in endothelial cells. It is required for vascular development 41, 42 and immune cell trafficking. 43, 44 As S1P, S1P1 has been linked to proinflammatory responses and anti-inflammatory responses. 10, 11 However, the use of a specific aortic endothelium S1P1 knock-out mouse strongly supports the anti-inflammatory role of S1P1, 13 which is in consonance with our findings in human endothelium. Along the same line, HDL promotes the formation of endothelial adherent functions and endothelial barrier function through ApoM-bound S1P and the S1P1 receptor. 5, 20, 22 Interestingly, it has been recently shown that S1P5 contributes to optimal barrier formation in the human brain endothelial cell line hCMEC/D3. 45 Still, S1P1 is the most abundant S1PR in hCMEC/D3. 45 Thus, cooperation between S1P1 and S1P5 is expected to maintain a proper blood-brain barrier. In contrast, there is an antagonist relationship between S1P1 and S1P2 in the vascular endothelium. Whereas S1P2 activation promotes vascular permeability and induces the expression of adhesion molecules, S1P1 signaling promotes the vascular barrier and reduces the expression of adhesion molecules. 9 In summary, a proper balance of S1PR is required to maintain a proper endothelial homeostasis.
The presence of several S1PR in vascular cells raises the question of how ApoM-bound S1P shows bias for a particular S1PR. It might be a simple matter of abundance or, A B Figure 7 . Apolipoprotein M (ApoM)-bound sphingosine-1-phosphate (S1P) is a more potent inhibitor of endothelial inflammation than albumin-bound S1P. A and B, HAEC treated with tumor necrosis factor-α (TNF-α) or TNF-α in the presence of (1) S1P bound to recombinant ApoM, (2) S1P in high-density lipoprotein (HDL), or (3) S1P bound to albumin were analyzed by flow cytometry for vascular adhesion molecule-1 (VCAM-1). In A, S1P concentrations from 0.01 to 0.5 μmol/L were explored. Data were normalized against TNF-α-treated HAEC. Two-way ANOVA, P=0.002, indicates that ApoM-bound S1P inhibition of VCAM-1 is larger than HDL inhibition and albumin-bound S1P inhibition. B corresponds to A when S1P is 0.1 μmol/L. One-way ANOVA P=0.006 followed by Holm-Sidak multiple comparison post hoc test. Bars show the mean of n=5. Error bars represent SD. *P<0.05.
alternatively, the location of S1PR in the plasma membrane (eg, in lipids rafts or caveolae) or the presence of coreceptors or adapter proteins (eg, SR-BI [scavenger receptor class B member 1] or another HDL receptor) could be also relevant. More studies are required to elucidate this question.
ApoM-Bound S1P Relevance in Atherosclerosis
ApoM has also been investigated in the context of atherosclerosis. Thus far, it is demonstrated that HDL +ApoM is more resistant to oxidation and promotes cholesterol efflux more efficiently than HDL −ApoM . 46, 47 Accordingly, overexpression of human ApoM or murine ApoM reduced the development of atherosclerotic lesions in low-density lipoproteins receptor knock-out mice 7, 48 and in ApoE knock-out mice. 49 During recent years, it has become clear that atherosclerosis is a chronic inflammatory pathology and, with the discovery of S1P as ApoM ligand, another factor came into the scene. Indeed, mice lacking S1P1 in the aorta develop more atherosclerotic plaques, and more macrophages infiltrate in the vessel wall. 13 Here, we report that ApoM-bound S1P specifically regulates VCAM-1, but not ICAM-1, in endothelial cells. This is remarkably relevant in atherosclerosis. Even though both ICAM-1 and VCAM-1 are elevated in atherosclerosis lesions, VCAM-1 plays a dominant role in the initiation of atherosclerosis. 50 Thus, ApoM-bound S1P anti-inflammatory role can be more prominent in early phases of the pathology and slow down atherosclerosis progress.
In summary, all these findings indicate that ApoM is a pleiotropic protein that could face atherosclerosis in different ways. However, more studies are required to fully understand ApoM biology and to use ApoM and S1PR as therapeutic targets in atherosclerosis.
Conclusions
Our study defines ApoM-bound S1P as a key component of HDL and is partially responsible for several HDL-associated protective functions in the endothelium, including regulation of adhesion molecule expression, leukocyte-endothelial adhesion, and endothelial barrier.
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